Document Detail

Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
MedLine Citation:
PMID:  22419641     Owner:  NLM     Status:  MEDLINE    
This open-label randomized trial compared isoniazid (9 months) to rifampin (4 months) on toxicity and completion in a jailed population with latent tuberculosis infection. Rifampin resulted in fewer elevated liver function tests (risk ratio [RR] 0.39, 95% confidence interval [CI] [0.18, 0.86]) and less toxicity requiring medication withdrawal (RR 0.51, 95% CI [0.13, 2.01]), although one participant receiving rifampin experienced an allergic reaction. Completion was achieved for 33% receiving rifampin compared to 26% receiving isoniazid (p = .10). With careful monitoring rifampin is a safe and less toxic regimen and appears to be a reasonable alternative because of its shorter duration, allowing more people to complete treatment behind bars. Therapy completion in released inmates is unacceptably low and ensuring follow-up after discharge must be part of a decision to treat.
Mary C White; Jacqueline P Tulsky; Ju Ruey-Jiuan Lee; Lisa Chen; Joe Goldenson; Joanne Spetz; L Masae Kawamura
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2012-03-14
Journal Detail:
Title:  Journal of correctional health care : the official journal of the National Commission on Correctional Health Care     Volume:  18     ISSN:  1940-5200     ISO Abbreviation:  J Correct Health Care     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-05-11     Completed Date:  2012-09-17     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  9503759     Medline TA:  J Correct Health Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  131-42     Citation Subset:  IM    
Department of Community Health Systems, School of Nursing, University of California, San Francisco, CA 94143, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antitubercular Agents / administration & dosage,  adverse effects,  therapeutic use*
Directly Observed Therapy
Isoniazid / administration & dosage,  adverse effects,  therapeutic use*
Latent Tuberculosis / drug therapy*
Liver Function Tests
Medication Adherence
Rifampin / administration & dosage,  adverse effects,  therapeutic use*
Socioeconomic Factors
Grant Support
U01 AI 51315/AI/NIAID NIH HHS; U01 AI051315-01A1/AI/NIAID NIH HHS; U01 AI051315-02/AI/NIAID NIH HHS; U01 AI051315-03/AI/NIAID NIH HHS; U01 AI051315-04/AI/NIAID NIH HHS; U01 AI051315-04S1/AI/NIAID NIH HHS; U01 AI051315-04S2/AI/NIAID NIH HHS
Reg. No./Substance:
0/Antitubercular Agents; 13292-46-1/Rifampin; 54-85-3/Isoniazid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Contraceptive Use and Barriers to Access Among Newly Arrested Women.
Next Document:  Chlamydia and Gonorrhea Screening Using Urine-Based Nucleic Acid Amplification Testing Among Males E...